Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

749.92 -3.49 (-0.46%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
The addressable market for the treatments could potentially contract significantly. 
Via The Motley Fool
Why Hims & Hers Health Stock Was Falling This Week
A new threat from Eli Lilly pushed the stock lower. 
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
Via Benzinga
Exploring The Competitive Space: Eli Lilly Versus Industry Peers In Pharmaceuticals
Via Benzinga
Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem. 
Via The Motley Fool
Warren Buffett's Berkshire Hathaway Breaks $1 Trillion: Poll Suggests Big Pharma, Not Tech, Is Next Contender
Warren Buffett is now the leader of a $1 trillion company with Berkshire Hathaway passing the milestone in August 2024 and joining an elite club. 
Via Benzinga
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Weight Loss
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and... 
Via Newsfile
Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock
It'll be a while before there's any impact, but it could be a big deal. 
Via The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space. 
Via Benzinga
Why Viking Therapeutics Stock Got Thrashed on Tuesday
A monster rival is making aggressive moves in one particular segment. 
Via The Motley Fool
Why Hims & Hers Stock Crashed on Tuesday
Could a competitor lowering prices eat into Hims & Hers market share? 
Via The Motley Fool
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
Why Hims & Hers Health Stock Is Falling
Eli Lilly's launch of the competitively priced Zepbound has triggered a 4.9% drop in Hims & Hers' stock. This has raised concerns over increased competition and potential market share loss. 
Via Benzinga
Eli Lilly's Stock Keeps Looking Better and Better. Here's the Latest Reason Why.
Its rock-star therapy looks like it could be marketed as a preventative treatment. 
Via The Motley Fool
Eli Lilly Slashes Zepbound Weight Loss Vial Prices By Up To 50% To Boost Access
Eli Lilly launches low-dose Zepbound vials for weight loss, offering 2.5 mg and 5 mg options for self-pay patients. These vials, priced at a significant discount compared to other GLP-1 obesity drugs,... 
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
Shareholders don't have too much to fear -- yet. 
Via The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited... 
Via Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes. 
Via MarketBeat
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed. 
Via Benzinga
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
The new drugs this company is developing could be worth a lot more than the present market value of its stock. 
Via The Motley Fool
Mounjaro Scores Yet Another Win: Why Eli Lilly Is Still a Buy
The drugmaker looks unstoppable. 
Via The Motley Fool
If You Like Eli Lilly, Then You'll Love This Little-Known Specialty Manufacturing Stock
Jacobs Solutions stands to be a beneficiary of the red-hot weight loss movement fueling the pharmaceutical market. 
Via The Motley Fool
Prediction: These Will Be the Best-Performing S&P 500 Stocks of 2024
The S&P 500's top three at year-end could look a little different than they do now. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
AskSlim Market Week - Friday, Aug. 23
An analysis and commentary on the financial markets. 
Via Talk Markets
Why Apple Stock And This 'Recession-Proof' Leader Strengthen Market's Bull Case
What happens when you get rate cuts as a tech revolution is starting? An environment that's set to supercharge the stock market, says this expert. 
Via Investor's Business Daily
Stock Market Rallies As Powell Confirms Rate Cuts; Palo Alto, Cava, Target Jump: Weekly Review
Palo Alto and Cava were among the earnings winners. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.